Since April, 2016, Dengvaxia—a dengue vaccine produced by Sanofi Pasteur (Lyon, France)—has been licensed for use in 19 countries. Dengvaxia was recommended by the WHO Strategic Advisory Group of Experts (SAGE) on immunisation to be used in regions with high endemicity, as defined by a prevalence of dengue antibodies of more than 50% in the targeted age group of people aged 9–45 years.¹ We have previously discussed the risks behind this vaccine recommendation,^2,3 and by analysing an age-structured model⁴ using the available vaccine trial data¹ predicted a significant reduction in dengue virus infection-related hospital admissions if Dengvaxia is given only to individuals who are seropositive for dengue antibodies.

中文翻译：

---

Dengvaxia：年龄是血清状况的替代物

自2016年4月起，由赛诺菲巴斯德（Sanofi Pasteur）（法国里昂）生产的登革热疫苗Dengvaxia已获准在19个国家使用。世卫组织免疫战略咨询专家组（SAGE）建议在登革热中使用高登革热，这是针对9-45岁目标人群中登革热抗体的流行率超过50％来定义的。¹，我们曾讨论过这背后疫苗建议，风险^2,3和通过分析年龄结构模型⁴使用可用的疫苗试验数据¹如果Dengvaxia只授予个人预测登革热病毒感染相关的住院一个显著减少对登革热抗体呈血清反应阳性。